Geron (GERN) Rockets 50% After Stem Cell Trial Cleared By FDA
More News related to ASTM
- Aastrom Biosciences (ASTM) Announces One-for-Eight Reverse Stock Split
- Aastrom Announces One-for-Eight Reverse Stock Split
- Biotech Stock Alert for Aastrom Biosciences Inc. Issued by InvestorSoup
- After-Hours Movers 1/21: SOMX, CNXT, ISRG, NRG Higher; SYNA, IBKR, ACHN, COF, NAT, GOOG Lower
- Aastrom Biosciences (ASTM)Closes 52.08M Common Unit Offering; Sees $12.4M Net Proceeds
More News related to GERN
- Geron to Present at the BIO CEO & Investor Conference
- Geron (GERN) Enters Collaboration to Study hESC-Based Product GRNOPC1
- Geron Forms Collaboration to Investigate GRNOPC1 in Alzheimer's Disease Models
- Geron (GERN) Announces Warrant Exchange: Investors to Buy 1.5M Shares at $6.75/Share
- Geron Corporation Announces Warrant Exchange
More News related to STEM
- Biopharmaceutical Stock Alert for StemCells Inc. Issued by Beacon Equity
- LifeTech Capital Initiates Research Coverage of StemCells, Inc. With Strong Speculative Buy Recommendation
- StemCells (STEM) Launches GS1-R for Germline Competent ES Rat Cells
- StemCells, Inc. Launches First Cell Culture Medium to Enable Derivation and Maintenance of True Rat Embryonic Stem Cells
- Biotech Stock Alert for StemCells Inc. Issued by Beacon Equity
More News related to Insiders' Blog
- Sprint (S): Q4 Earnings Preview
- NYSE Euronext (NYX) Beats the Street's Q4 Views on Both the Top and Bottom Lines
- Q1 Earnings Preview: Walt Disney (DIS)
- S&P Revises Credit Outlooks On BofA (BAC) and Citi (C) to Negative, Saying No More Free Govenment Handouts
- Airline Stocks Taking-Off as UAL Reports Strong Monthly Traffic Results; Investors Shrug at Flight Delays (UAUA, DAL, LUV, AMR, more)
Geron Corporation (Nasdaq: GERN) is continuing to rocket higher following news this morning that the FDA has granted clearance of the company’s Investigational New Drug (IND) application for the clinical trial of GRNOPC1 in patients with acute spinal cord injury. Geron said this is the world's first human clinical trial of embryonic stem cell-based therapy. The stock is now up 50%.
Geron competitors are also higher on the news: Aastrom Biosciences, Inc. (Nasdaq: ASTM) is up 30% and StemCells Inc. (Nasdaq: STEM) is up 30%.
Related Categories
Insiders' BlogMomentum Movers
Stocks Mentioned
-0.03
+0.01Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
